Screener
Boston Scientific BSX Interventional Cardiology & Vascular Therapies — Net Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 6:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885725-26-000033
| Businesses | Three Months Ended March 31, 2026 / U.S. | Three Months Ended March 31, 2026 / Int'l | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / U.S. | Three Months Ended March 31, 2025 / Int'l | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Urology | 465 | 182 | 646 | 469 | 165 | 633 |
| Neuromodulation | 236 | 82 | 318 | 204 | 67 | 271 |
| MedSurg | 1,147 | 554 | 1,701 | 1,093 | 484 | 1,577 |
| Interventional Cardiology & Vascular Therapies | 552 | 692 | 1,244 | 467 | 657 | 1,124 |
| Watchman | 462 | 44 | 506 | 390 | 34 | 425 |
| Electrophysiology | 603 | 302 | 905 | 511 | 219 | 730 |
| Cardiac Rhythm Management | 349 | 229 | 578 | 358 | 220 | 578 |
| Interventional Oncology & Embolization | 170 | 99 | 268 | 142 | 87 | 228 |
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Boston Scientific's interventional cardiology & vascular therapies — net sales?
- Boston Scientific (BSX) reported interventional cardiology & vascular therapies — net sales of $1.24B in Q1 2026.
- How has Boston Scientific's interventional cardiology & vascular therapies — net sales changed year-over-year?
- Boston Scientific's interventional cardiology & vascular therapies — net sales increased by 10.7% year-over-year, from $1.12B to $1.24B.
- What is the long-term trend for Boston Scientific's interventional cardiology & vascular therapies — net sales?
- Over 3 years (2021 to 2024), Boston Scientific's interventional cardiology & vascular therapies — net sales has grown at a 6.2% compound annual growth rate (CAGR), from $2.21B to $2.65B.
- What does interventional cardiology & vascular therapies — net sales mean?
- This metric represents the total revenue generated from the sale of medical devices and technologies specifically designed for interventional cardiology procedures, such as coronary stents, balloon catheters, and imaging systems. It reflects the company's market penetration and commercial success in treating cardiovascular diseases through minimally invasive techniques. This revenue stream is a primary driver of the company's overall financial performance within the medical device sector.
Ask your AI about Boston Scientific's interventional cardiology & vascular therapies — net sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude